SeraCare Life Sciences Continues to Expand Product Portfolio

MILFORD, Mass., Sept. 7, 2011 /PRNewswire/ -- SeraCare Life Sciences (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that the Company has introduced six new offerings to its product portfolio – SeraSure^® Fetal Bovine Serum (FBS), a cell culture growth medium, three new cellular products in the AccuCell^® Peripheral Blood Mononuclear Cell (PBMC) portfolio and two new HPV DNA controls in the ACCURUN^® line.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )

"With 17 products launched to-date this year, SeraCare has already exceeded our goal of introducing 12 new products in fiscal year 2011," said Greg Gould, Interim Chief Executive Officer and Chief Financial Officer. "SeraSure FBS exemplifies our ability to continuously raise the bar for quality and purity standards in biological research materials. The new HPV controls and PBMC cellular products are part of our commitment to offer customers increased flexibility within the same trusted, best-in-class product lines."

New product highlights:
SeraSure FBS is tested by a highly-sensitive PCR assay for bovine viral diarrhea (BVD) virus and is the result of a rigorous, segregated production process to assure that the end product is BVD virus negative. Commercial FBS is nearly universally positive for the virus but SeraSure FBS offers customers access to a rare, PCR-tested BVD-negative product for their cell culture needs in applications where BVD could interfere with downstream results.

The ACCURUN^® 372 Series 600 HPV DNA Positive Control and ACCURUN^® 872 HPV DNA Negative Control products expand the range of assay compatibility in the most common transport media for SeraCare's independent, whole cell controls. These products are designed to challenge, troubleshoot and improve HPV assay performance for multiple sample matrices.

Cryo-T4 Human CD4+ T-cells, Cryo-T8 Human CD8+ T-cells and Cryo-B Human CD19+ B-cells are new cellular products added to the AccuCell PBMC portfolio. These are the fourth, fifth, and sixth cellular types launched in the SeraCare AccuCell PBMC portfolio, respectively, and are part of SeraCare's program to continually expand the breadth and variety of its readily-available, off-the-shelf PBMC Subsets. Cryopreserved primary cells are especially valuable for use in the study of autoimmune disease, inflammatory disease, oncology and infectious disease. Each AccuCell product includes a broad range of donor demographics and characterization information.

About SeraCare Life Sciences, Inc.
SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). For example, all statements regarding the future of our recently introduced and anticipated new products are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, the risk that the introduction of new products may be delayed and uncertainty regarding market acceptance of our new products. Many of these factors are beyond our ability to control or predict.

Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060

SOURCE SeraCare Life Sciences